Your browser doesn't support javascript.
loading
Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS.
Prieto-Alhambra, Daniel; Kostka, Kristin; Duarte-Salles, Talita; Prats-Uribe, Albert; Sena, Anthony; Pistillo, Andrea; Khalid, Sara; Lai, Lana; Golozar, Asieh; Alshammari, Thamir M; Dawoud, Dalia; Nyberg, Fredrik; Wilcox, Adam; Andryc, Alan; Williams, Andrew; Ostropolets, Anna; Areia, Carlos; Jung, Chi Young; Harle, Christopher; Reich, Christian; Blacketer, Clair; Morales, Daniel; Dorr, David A; Burn, Edward; Roel, Elena; Tan, Eng Hooi; Minty, Evan; DeFalco, Frank; de Maeztu, Gabriel; Lipori, Gigi; Alghoul, Heba; Zhu, Hong; Thomas, Jason; Bian, Jiang; Park, Jimyung; Roldán, Jordi Martínez; Posada, Jose; Banda, Juan M; Horcajada, Juan P; Kohler, Julianna; Shah, Karishma; Natarajan, Karthik; Lynch, Kristine; Liu, Li; Schilling, Lisa; Recalde, Martina; Spotnitz, Matthew; Gong, Mengchun; Matheny, Michael; Valveny, Neus.
Affiliation
  • Prieto-Alhambra D; Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDROMS), University of Oxford, UK.
  • Kostka K; Real World Solutions, IQVIA, Cambridge, MA, USA.
  • Duarte-Salles T; Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
  • Prats-Uribe A; Centre for Statistics in Medicine, University of Oxford.
  • Sena A; Janssen R&D, Titusville NJ, USA, 2) Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Pistillo A; Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
  • Khalid S; Centre for Statistics in Medicine, NDORMS, University of Oxford, UK.
  • Lai L; Division of Cancer Sciences, School of Medical Sciences, University of Manchester, UK.
  • Golozar A; Regeneron Pharmaceuticals, NY USA, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, MD USA.
  • Alshammari TM; Medication Safety Research Chair, King Saud University, Riyadh, Saudi Arabia.
  • Dawoud D; National Institute for Health and Care Excellence, London, UK.
  • Nyberg F; School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Wilcox A; Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, WA, USA, 2) UW Medicine, Seattle, WA, USA.
  • Andryc A; Janssen R&D, Titusville NJ, USA.
  • Williams A; Tufts Institute for Clinical Research and Health Policy Studies, US.
  • Ostropolets A; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY 10032, USA.
  • Areia C; Nuffield Department of Clinical Neurosciences, University of Oxford, UK.
  • Jung CY; Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu, Korea.
  • Harle C; University of Florida Health, Gainesville, FL, USA.
  • Reich C; Real World Solutions, IQVIA, Cambridge, MA, USA.
  • Blacketer C; Janssen R&D, Titusville NJ, USA, 2) Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Morales D; Division of Population Health and Genomics, University of Dundee, UK.
  • Dorr DA; Department of Medical Informatics & Clinical Epidemiology, Oregon Health & Science University, Portland, OR, USA.
  • Burn E; Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
  • Tan EH; Centre for Statistics in Medicine, NDORMS, University of Oxford, UK.
  • Minty E; O'Brien Institute for Public Health, Faculty of Medicine, University of Calgary, Canada.
  • DeFalco F; Janssen R&D, Titusville NJ, USA.
  • de Maeztu G; IOMED, Barcelona, Spain.
  • Lipori G; University of Florida Health.
  • Alghoul H; Faculty of Medicine, Islamic University of Gaza, Palestine.
  • Zhu H; Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Thomas J; Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, WA, USA.
  • Bian J; University of Florida.
  • Park J; Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Korea.
  • Roldán JM; Director of Innovation and Digital Transformation, Hospital del Mar, Barcelona, Spain.
  • Posada J; Stanford University School of Medicine, Stanford, California, USA.
  • Banda JM; Georgia State University, Department of Computer Science, Atlanta, GA, USA.
  • Horcajada JP; Department of Infectious Diseases, Hospital del Mar, Institut Hospital del Mar d'Investigació Mèdica (IMIM), Universitat Autònoma de Barcelona. Universitat Pompeu Fabra, Barcelo.
  • Kohler J; United States Agency for International Development, Washington, DC, USA.
  • Shah K; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
  • Natarajan K; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY 10032, USA, 2) New York-Presbyterian Hospital, 622 W 168 St, PH20 New York, NY 10032 USA.
  • Lynch K; VINCI, VA Salt Lake City Health Care System, Salt Lake City, VA, & Division of Epidemiology, University of Utah, Salt Lake City, UT.
  • Liu L; Biomedical Big Data Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Schilling L; Data Science to Patient Value Program, University of Colorado Anschutz Medical Campus.
  • Recalde M; Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
  • Spotnitz M; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY 10032, USA.
  • Gong M; DHC Technologies Co. Ltd, Beijing, China.
  • Matheny M; VINCI, Tennessee Valley Healthcare System VA, Nashville, TN & Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN.
  • Valveny N; Real-World Evidence, TFS, Barcelona, Spain.
Res Sq ; 2021 Mar 01.
Article in En | MEDLINE | ID: mdl-33688639
Background: Routinely collected real world data (RWD) have great utility in aiding the novel coronavirus disease (COVID-19) pandemic response [1,2]. Here we present the international Observational Health Data Sciences and Informatics (OHDSI) [3] Characterizing Health Associated Risks, and Your Baseline Disease In SARS-COV-2 (CHARYBDIS) framework for standardisation and analysis of COVID-19 RWD. Methods: We conducted a descriptive cohort study using a federated network of data partners in the United States, Europe (the Netherlands, Spain, the UK, Germany, France and Italy) and Asia (South Korea and China). The study protocol and analytical package were released on 11 th June 2020 and are iteratively updated via GitHub [4]. Findings: We identified three non-mutually exclusive cohorts of 4,537,153 individuals with a clinical COVID-19 diagnosis or positive test, 886,193 hospitalized with COVID-19 , and 113,627 hospitalized with COVID-19 requiring intensive services . All comorbidities, symptoms, medications, and outcomes are described by cohort in aggregate counts, and are available in an interactive website: https://data.ohdsi.org/Covid19CharacterizationCharybdis/. Interpretation: CHARYBDIS findings provide benchmarks that contribute to our understanding of COVID-19 progression, management and evolution over time. This can enable timely assessment of real-world outcomes of preventative and therapeutic options as they are introduced in clinical practice.

Full text: 1 Database: MEDLINE Type of study: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Res Sq Year: 2021 Type: Article

Full text: 1 Database: MEDLINE Type of study: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Res Sq Year: 2021 Type: Article